TREMFYA ® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies

Findings from the DISCOVER-1 and DISCOVER-2 studies are presented, for the first time, at the 2019 American College of Rheumatology and Association of Rheumatology Professionals Annual MeetingThese are the first Phase 3 results evaluating p19-specific IL-23 inhibition in active psoriatic arthritis
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Dalmády S, Kemény L, Antal M, Gyulai R Abstract Introduction: Psoriasis is a chronic autoimmune skin disease with strong genetic background and environmental triggers. Patients with psoriasis and psoriatic arthritis are at greater risk of developing other chronic and potentially severe comorbidities, such as psoriatic arthritis, hyperlipidemia, type 2 diabetes mellitus, obesity, metabolic syndrome, cardiovascular diseases or depression. Recently, accumulating epidemiologic, genetic and pathogenetic evidence indicates that psoriasis is also associated with periodontitis, a chronic progressive ...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
Background: Few studies have evaluated the effectiveness of adalimumab in the real-life setting in psoriatic arthritis (PsA).Objective: To evaluate the 2-year retention rate of adalimumab in PsA patients. Potential baseline parameters influencing persistence on treatment were also evaluated.Methods: PsA patients from 16 Italian Rheumatology Units treated with adalimumab as first- or second-line biological therapy were retrospectively evaluated. Adalimumab retention rate was evaluated at 12 and 24 months. Logistic regression was used to evaluate the association between predictor variables and adalimumab retention rate.Resul...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 11 December 2019Source: Best Practice &Research Clinical Endocrinology &MetabolismAuthor(s): Poupak Fallahi, Giusy Elia, Francesca Ragusa, Ilaria Ruffilli, Stefania Camastra, Claudia Giusti, Sabrina Rosaria Paparo, Debora Gonnella, Yehuda Shoenfeld, Silvia Martina Ferrari, Alessandro AntonelliAbstractAutoimmune thyroid diseases (AITD) are organ-specific autoimmune disorders mediated by Th1 lymphocytes, whose main clinical presentations are Hashimoto’s thyroiditis (HT), or Graves’ disease (GD). HT, GD, thyroid autoantibodies and thyroid dysfunctions have been shown in s...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research
CONCLUSIONS: By combining manual and automated data analysis, our study revealed several disease-specific immune cell subpopulations, particularly cytotoxic T-cell subsets in RA and memory B-cell subsets in AS, which may serve as an indicator of active disease or possible therapeutic target. PMID: 31820725 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Gene Variant in the NF-κB Pathway Inhibitor NFKBIA Distinguishes Patients with Psoriatic Arthritis within the Spectrum of Psoriatic Disease. Biomed Res Int. 2019;2019:1030256 Authors: Coto-Segura P, Coto E, González-Lara L, Alonso B, Gómez J, Cuesta-Llavona E, Queiro R Abstract Background and Aims: The NF-κB pathway has been implicated in the genetic aetiology of psoriatic disease. However, since most patients with arthritis have psoriasis, discerning the genetic contributions to both aspects of psoriatic disease is not easy. Our aim was to study the association of common pol...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
This review examined the impact of weight loss on pre-existing psoriasis or psoriatic arthritis. Might losing weight prevent the onset of psoriasis in obese individuals?The British Journal of Dermatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
n P Abstract Psoriatic arthritis (PsA) is a heterogeneous multifactorial disease with musculoskeletal involvement, which can be manifested as monoarthritis, oligoarthritis or polyarthritis and in some patients can also affect the axial skeleton. The most frequent indications of inflammation are bone marrow edema and enthesitis. The early and differential diagnosis of PsA is a clinical challenge, particularly as a differential diagnosis from other inflammatory or degenerative diseases of joints. Inflammatory joint and tendon alterations in the region of the extremities and the spine can be visualized with high sens...
Source: Zeitschrift fur Rheumatologie - Category: Rheumatology Authors: Tags: Z Rheumatol Source Type: research
Conditions:   Psoriatic Arthritis;   Inflammatory Bowel Diseases Intervention:   Diagnostic Test: Fecal calprotectin assay Sponsors:   Hospital of Prato;   Giulia Franchi,Department of Rheumatology, Hospital of Prato;   Maurizio Benucci,S.Giovanni di Dio Hospital;   Raffaele Scarpa, Rheumatology Unit, University of Naples Federico II, Naples;   Francesco Caso, Rheumatology Unit, University of Naples Federico II, Naple s;   Rosario Foti,Rheumatology Unit, A.O.U. Policlinico Vittorio Emanuele, Catania;   Antonio...
Source: - Category: Research Source Type: clinical trials
ConclusionsThere are HLA differences in Chinese patients with EP compared with patients with PV. The incidence of psoriatic arthritis is also higher. The implications of the above findings await further investigation.
Source: Molecular Diagnosis and Therapy - Category: Molecular Biology Source Type: research
AbstractPurpose of ReviewThe therapeutic response to biologic agents in psoriasis is significantly higher than observed in psoriatic arthritis (PsA). In this review, specific actions to improve treatment outcomes in PsA are discussed.Recent FindingsIncreased understanding of disease pathogenesis derived from improved preclinical models and advances in cell-based and molecular technologies provide new tools to identify therapeutic targets. In addition to the important contributions of metabolic comorbidities, chronic pain and the lack of a diagnostic biomarker signal the need for new strategies to improve outcomes. Potentia...
Source: Current Rheumatology Reports - Category: Rheumatology Source Type: research
More News: Arthritis | Pharmaceuticals | Psoriatic Arthritis | Rheumatology | Study